"The Oncology Drug Marketplace: Trends in Discounting and Site of Care." A new study of trends in the 340B Drug Discount Program, released today by the Community Oncology Alliance (COA), finds that the average profit margin on oncology drugs purchased by hospitals through the 340B program has grown to 49 percent in 2015. At the same time, 340B discounts provided by manufacturers have exploded, leading to pricing pressure on cancer drugs.
"The Oncology Drug Marketplace: Trends in Discounting and Site of Care." A new study of trends in the 340B Drug Discount Program, released today by the Community Oncology Alliance (COA), finds that the average profit margin on oncology drugs purchased by hospitals through the 340B program has grown to 49 percent in 2015. At the same time, 340B discounts provided by manufacturers have exploded, leading to pricing pressure on cancer drugs.